Showing 1 - 10 of 288
how consumers respond to drug withdrawals. In theory, remaining drugs in the therapeutic class could enjoy competitive …
Persistent link: https://www.econbiz.de/10012467462
The extent of pharmaceutical advertising and promotion can be characterized by a balancing act between profitable demand expansions and potentially unfavorable subsequent regulatory actions. However, this balance also depends on the nature of competition (e.g. monopoly versus oligopoly). In this...
Persistent link: https://www.econbiz.de/10012461495
We establish four facts concerning competition among U.S. generic drug suppliers, using IQVIA's National Sales Perspective™ 2004Q4 - 2016Q3 data. We define a unique product market ("molform"), consisting of the combination of a molecule active ingredient and a route of administration...
Persistent link: https://www.econbiz.de/10012480138
Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic competition after entry. However, less attention has been paid to pricing behavior in anticipation of brand-to-brand competition. We contribute to this gap in the literature by both...
Persistent link: https://www.econbiz.de/10012453327
Drug pricing in the U.S. is a persistently vexing policy problem. While there is agreement among many policy analysts that supra competitive prices are necessary to promote innovation; significant disagreements arise over how much pricing discretion prescription drug manufacturers should be...
Persistent link: https://www.econbiz.de/10012453473
Inefficiency in the U.S. health care system has often been characterized as "flat of the curve" spending providing little or no incremental value. In this paper, we draw on macroeconomic models of diffusion and productivity to better explain the empirical patterns of outcome improvements in...
Persistent link: https://www.econbiz.de/10012463783
This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across a large sample of countries. We focus on drugs to treat HIV/AIDS, TB and malaria in middle and low income countries (MLICs), with robustness checks to other therapeutic categories and other...
Persistent link: https://www.econbiz.de/10012461483
Persistent link: https://www.econbiz.de/10000056090
"We prove that the change in welfare of a representative consumer is summarized by the current and expected future values of the standard Solow productivity residual. The equivalence holds if the representative household maximizes utility while taking prices parametrically. This result justifies...
Persistent link: https://www.econbiz.de/10011394520
Persistent link: https://www.econbiz.de/10001686747